Zila to Introduce New and Improved Ester-C; Commercialization Efforts Nearly Complete for New Patented Product

PHOENIX, May 02, 2006 (BUSINESS WIRE) -- Zila, Inc., (ZILA) announced that its wholly owned subsidiary, Zila Nutraceuticals, Inc., manufacturer of Ester-C(R) and Ester-E(R), has developed a new and improved form of its Ester-C product and that the patent protection for this new form of Ester-C extends until 2019. Ester-C is the most widely recognized branded nutraceutical ingredient in the United States. The new product offers all the benefits of Zila's traditional Ester-C plus an additional metabolite with new benefits. Following years of research and development, the new Ester-C product is nearly ready for commercial distribution.
"We are extremely pleased to be able to continue to provide a patent protected and superior form of vitamin C to the loyal consumers of our Ester-C product. This new product has been designed to enhance the antioxidant and anti-carcinogenic potential of our existing Ester-C formula and the patent protection for it will last until 2019. We will be working with our customers to assure a smooth transition to this new product as we get closer to the product launch date." said Douglas D. Burkett, Ph.D., Chairman, Chief Executive Officer and President of Zila, Inc.

About Ester-C(R)
Ester-C is an advanced form of vitamin C that is pH neutral, providing a form that is gentler on the stomach than regular vitamin C. During the patented process of producing Ester-C, the vitamin C undergoes changes similar to those that occur in the body, which results in enhanced levels of valuable metabolites. Ester-C has also been clinically proven to work in the immune system for 24 hours. Additional clinical studies and product claims are planned.

About Ester-E(R)
Ester-E is an advanced form of vitamin E containing d-alpha tocopheryl phosphates (or "TP" for short). Until recently, scientists were unaware of this important source of vitamin E in the body. Research suggests that the human body may convert other forms of vitamin E into TP in order to protect the vitamin's antioxidant strength. Scientists are now able to replicate this natural form of vitamin E (Ester-E) in a patented process, preserving vitamin E's natural health benefits so that it can be more effectively used by the body.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Visit www.Ester-E.com or www.Ester-C.com for more information about the "Ester" line of premium products.

About Zila, Inc.
Zila, Inc., headquartered in Phoenix, is an innovator in preventative healthcare technologies and products, focusing on enhanced body defense and the detection of pre-disease states. Zila has three business units:

-- Zila Biotechnology, a research, development and licensing business specializing in pre-cancer/cancer detection through its patented Zila(R) Tolonium Chloride and OraTest(R) technologies.

-- Zila Pharmaceuticals, marketer of products to promote oral health and prevent oral disease, including ViziLite(R) Plus oral examination kits and Peridex(R) prescription periodontal rinse.

-- Zila Nutraceuticals, manufacturer and marketer of Ester-C(R) and Ester-E(R), branded, highly effective forms of Advanced Protection vitamins C and E.

-- For more information about Zila, visit www.zila.com.
his press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on Zila's expectations or forecasts of future events, can be affected by inaccurate assumptions and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the Company's control. Therefore, actual results could differ materially from the forward-looking statements contained herein. A wide variety of factors could cause or contribute to such differences and could adversely impact revenues, profitability, cash flows and capital needs. There can be no assurance that the forward-looking statements contained in this press release will, in fact, transpire or prove to be accurate. For a more detailed description of these and other cautionary factors that may affect Zila's future results, please refer to Zila's Form 10-K for its fiscal year ended July 31, 2005.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.